185 related articles for article (PubMed ID: 37533028)
1. Fine-grained mathematical modeling for cost-effectiveness evaluation of public health policies for cervical cancer, with application to a Colombian case study.
Angulo D; Cortes MF; Mura I; Akhavan-Tabatabaei R
BMC Public Health; 2023 Aug; 23(1):1470. PubMed ID: 37533028
[TBL] [Abstract][Full Text] [Related]
2. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
4. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
5. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
[TBL] [Abstract][Full Text] [Related]
6. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.
Aponte-González J; Fajardo-Bernal L; Diaz J; Eslava-Schmalbach J; Gamboa O; Hay JW
PLoS One; 2013; 8(11):e80639. PubMed ID: 24260441
[TBL] [Abstract][Full Text] [Related]
8. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
9. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
14. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
15. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
18. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
19. Mathematical Models for Evaluating Effectiveness and Cost-Effectiveness of Cervical Cancer Control Policies in Populations Including Women Living With Human Immunodeficiency Virus: A Scoping Review.
Iskandar R; Taghavi K; Low N; Bramer WM; Egger M; Rohner E
Value Health Reg Issues; 2022 Nov; 32():39-46. PubMed ID: 36063639
[TBL] [Abstract][Full Text] [Related]
20. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
